Potential pathways of abnormal tau and α-synuclein dissemination in sporadic Alzheimer’s and Parkinson’s diseases

Cold Spring Harbor Perspectives in Biology

Volumn 8, Issue 11, 2016, Pages

  Braak, Heiko ^a   Del Tredici, Kelly ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN;

ALZHEIMER DISEASE; HUMAN; METABOLISM; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; HUMANS; PARKINSON DISEASE; TAU PROTEINS;

EID: 84994614108     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a023630     Document Type: Article

References (235)

1. Adler CH, Dugger BN, Hinni ML, Lott DG, Driver-Dunckley E, Hidalgo J, Henry-Watson J, Serrano G, Sue LI, Nagel T, et al. (2014). Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 82: 858-864.
2. Agnati LF, Bjekle B, Fuxe K. (1995). Volume versus wiring transmission in the brain: A new theoretical frame of neuropsychopharmacology. Med Res Rev 15: 33-45.
3. Aguzzi A. (2009). Beyond the prion principle. Nature 459: 924-925.
4. Aguzzi A, Calella AM. (2009). Prions: Protein aggregation and infectious diseases. Physiol Rev 89: 1105-1152.
5. Aguzzi A, Rajendran L. (2009). The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64: 783-790.
6. Ahmed Z, Cooper J, Murray TK, Gara K, McNaughton E, Clarke H, Parhizkar S, Ward MA, Cavallini A, Jackson S, et al. (2014). A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 127: 667-683.
7. Alafuzoff I, Thal DR, Arzberger T, Bodganovic N, Al-Sarraj S, Bodi I, Boluda S, BugianiO, Buckaerts C, Gelpi E, et al. (2009). Assessment of b-amyloid deposits in human brain: A study of the BrainNet Europe Consortium. ActaNeuropathol 117: 309-320.
8. Alheid GF. (2003). Extended amygdala and basal forebrain. Ann NYAcad Sci 985: 185-205.
9. Angot E, Steiner JA, Hansen C, Li JY, Brundin P. (2010). Are synucleinopathies prion-like disorders? Lancet Neurol 9: 1128-1138.
10. Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björkland B, Brundin P. (2012). α-Synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS ONE 7: e39465.
11. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. (2001). α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: Morphology and its relationship to tau aggregation. Brain Res 888: 287-296.
12. Arnold SE, Lee EB,Moberg PF, Stutzbach L, Kazi H, Han LY, Lee VM, Trojanowski JQ. (2010). Olfactory epithelium and amyloid-b and paired helical filament-tau pathology in Alzheimer’s disease. Ann Neurol 67: 462-469.
13. Aston-Jones G, Cohen JD. (2005). Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol 493: 99-110.
14. Attems J, Jellinger KA. (2006). Olfactory tau pathology in Alzheimer’s disease and mild cognitive impairment. Clin Neuropathol 25: 265-271.
15. Bannister AP. (2005). Inter- and intra-laminar connections of pyramidal cells in the neocortex. Neurosci Res 53: 95-103.
16. Barbas H. (2007). Specialized elements of orbitofrontal cortex in primates. Ann NY Acad Sci 1121: 10-32.
17. Beach TG,White CK III, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, et al. (2009). Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117: 169-174.
18. Beach TG, Adler CH, Sue LI, Vedders L, Lue L,White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, et al. (2010).Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119: 689-702.
19. Beach TG, Adler CH, Dugger BN, Serrano G, Hildalgo J, Henry-Watson I, Shill HA, Sue LI, Sabbagh MN, Akivama H, et al. (2013). Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 72: 130-136.
20. Beekes M, Thomzig A, Schulz-Schaeffer WJ, Burger R. (2014). Is there a risk of prion-like disease transmission by Alzheimer or Parkinson-associated protein particles? Acta Neuropathol 128: 463-476.
21. Benarroch EE. (2007). Enteric nervous system: Functional organization and neurologic implications. Neurology 69: 1953-1957.
22. Benarroch EE. (2009). The locus ceruleus norepinephrine system: Functional organization and potential clinical significance. Neurology 73: 1699-1704.
23. Bernis ME, Babila JT, Breid S, Wüsten KA, Wüllner U, Tamgüney G. (2015). Prion-like propagation of human brain-derived α-synuclein in transgenic mice expressing wild-type α-synuclein. Acta Neuropathol Comm 3: 75.
24. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. (2006). α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 12: 284-295.
25. Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Böckmann A,Meier BH, et al. (2013). Structural and functional characterization of two α-synuclein strains. Nat Comm 4: 2575.
26. Braak H. (1980). Architectonics of the human telencephalic cortex, pp. 1-147. Springer, Berlin.
27. Braak H, Braak E. (1992). The human entorhinal cortex: Normal morphology and laminα-specific pathology in various diseases. Neurosci Res 15: 6-31.
28. Braak H, Del Tredici K. (2009). Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv Anat Embryol Cell Biol 201: 1-119.
29. Braak H, Del Tredici K. 2011a. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121: 171-181.
30. Braak H, Del Tredici K. 2011b. Alzheimer’s pathogenesis: Is there neuron-to-neuron propagation? Acta Neuropathol 121: 589-595.
31. Braak H, Del Tredici K. (2013). Evolutional aspects of Alzheimer’s disease pathogenesis. JAlzheimers Dis 33: S155-S161.
32. Braak H, Del Tredici K. (2014). Are caseswith tau pathology in the absence of Ab deposits part of the AD-related pathological process? Acta Neuropathol 128: 767-772.
33. Braak H, Del Tredici K. 2015a. Neuroanatomy and pathology of sporadic Alzheimer’s disease. Adv Anat Embryol Cell Biol 215: 1-162.
34. Braak H, Del Tredici K. 2015b. The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain 138: 2814-2833.
35. Braak E, Braak H, Mandelkow EM. 1994a. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87: 554-567.
36. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K. 1994b. Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88: 493-500.
37. Braak H, Sandmann-Keil D, Gai WP, Braak E. (1999). Extensive axonal Lewy neurites in Parkinson’s disease: A novel pathological feature revealed by α-synuclein. Neurosci Lett 265: 67-69.
38. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. 2003a. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24: 197-211.
39. Braak H, Rüb U, Gai WP, Del Tredici K. 2003b. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536.
40. Braak H, de Vos RAI, Bohl J, Del Tredici K. (2006). Gastric asynuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396: 67-72.
41. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. (2007). Parkinson’s disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113: 421-429.
42. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. (2011). Stages of the pathologic process in Alzheimer disease:Age categories from 1 to 100 years. J Neuropathol Exp Neurol 70: 960-969.
43. Brandel JP, Corbillé AG, Derkinderen P, Haïk S. (2015). [Is Parkinson’s disease a prion disease?] Rev Neurol (Paris) 171: 812-824.
44. Brelstaff J, Ossola B, Neher JJ, Klingstedt T, Nilsson KPR, Goedert M, Spillantini MG, Tolkovsy AM. (2015). The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Front Neurosci 9: 184.
45. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. (2008). Research in motion: The enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 9: 741-745.
46. Brundin P,Melki R, Kopito R. (2010). Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11: 301-307.
47. Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Stropper B, de Wit J, Verstreken P, Moechars D. (2015). Synaptic contacts enhance cell-to-cell tau pathology propagation. Cell Rep 11: 1176-1183.
48. Cersósimo MG, Benarroch EE. (2008). Neural control of the gastrointestinal tract: Implications for Parkinson disease. Mov Disord 23: 1065-1075.
49. Cersósimo MG, Perandonas C, Micheli FE, Raina GB, Beron AM, Nasswetter G, Radrizzani M, Benarroch EE. (2011). α-Synuclein immunoreactivity in minor salivary gland biopsies of Parkinson’s disease patients. Mov Disord 26: 188-190.
50. Ciechanover A. (2005). Proteolysis: From the lysome to ubiquitin and the proteasome. Nat Rev Moll Cell Biol 6: 79-87.
51. Chung KK, Dawson VL, Dawson TM. (2001). The role of the ubiquitin-proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci 24: 7-14.
52. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, et al. (2009). Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11: 909-913.
53. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, et al. 2013a. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci 110: 9535-9540.
54. Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M. 2013b. "Prion-like" template misfolding in tauopathies. Brain Pathol 23: 342-349.
55. Collingridge GL, James TA, MacLeod NK. (1979). Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra. J Physiol 290: 44.
56. Cookson MR. (2006). Hero versus antihero: The multiple roles of α-synuclein in neurodegeneration. Exp Neurol 199: 238-242.
57. Counts SE,Mufson EJ. (2012). Locus coeruleus. In The human nervous system, 3rd ed. (ed. Mai JK, Paxinos G), pp. 425-438. Academic, New York.
58. Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. (1992). Relationships between Lewy bodies and pale bodies in Parkinson’s disease. Acta Neuropathol 83: 525-529.
59. DeLong MR, Wichmann T. (2007). Circuits and circuit disorders of the basal ganglia. Arch Neurol 64: 20-24.
60. Del Tredici K, Braak H. (2012). Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathol 124: 643-664.
61. Del Tredici K, Braak H. (2013). Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry 84: 774-783.
62. Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H. (2002). Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61: 413-426.
63. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. (2010). Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119: 703-713.
64. den Hartog Jager WA, Bethlem J. (1960). The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 23: 283-290.
65. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. (2009). Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci 106: 13010-13015.
66. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, et al. (2009). Neuropathological assessment of Parkinson disease: Refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.
67. Doty RL. (2008). The olfactory vector hypothesis of neurodegenerative diseases: Is it viable? Ann Neurol 63: 7-15.
68. Duda JE, ShahU, Arnold SE, Lee VM, Trojanowski JQ. (1999). The expression of α-, β-, and γ-synucleins in olfactory mucosa. Exp Neurol 160: 515-522.
69. Duda JE, Giasson BI, Lee VM, Trojanowski JQ. (2006). Is the initial insult in Parkinson’s disease and dementia with Lewy bodies a neuritic dystrophy? Ann NY Acad Sci 991: 295-297.
70. Dugger BN, Dickson DW. (2010). Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol 120: 633-639.
71. Dujardin S, Lécolle K, Caillierez R, Bégard S, Zommer N, Lachaud C, Carrier S, Dufour N, Aurégan G,Winderickx J, et al. (2014). Neuron-to-neuron wild-type tau protein transfer through a trans-synaptic mechanism: Relevance to sporadic tauopathies. ActaNeuropatholCommun 2: 14.
72. Dunning CJ, Reyes JF, Steiner JA, Brundin P. (2011). Can Parkinson’s disease pathology be propagated from one neuron to another? Progr Neurobiol 97: 205-219.
73. Duyckaerts C. (2013). Neurodegenerative lesions: Seeding and spreading. Rev Neurol 169: 825-833.
74. Duyckaerts C, Uchihara T, Seilhean D, He Y, Hauw JJ. (1997). Dissociation of Alzheimer type pathology in a disconnected piece of cortex. Acta Neuropathol 93: 501-507.
75. Eadie MJ. (1963). The pathology of certain medullary nuclei in Parkinsonism. Brain 86: 781-792.
76. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. (2012). Protein degradation pathways in Parkinson’s disease: Curse or blessing? Acta Neuropathol 124: 153-172.
77. Eisenberg D, Jucker M. (2012). The amyloid state of proteins in human diseases. Cell 148: 1188-1203.
78. Falcon B, Cavallini A, Angers R, Glover S,Murray TK, Barnham L, Jackson S, O’Neill MJ, Isaacs AM, Hutton ML, et al. (2015). Conformation determines the seeding potencies of native and recombinant tau aggregates. J Biol Chem 290: 1049-1065.
79. Fiala JC. (2007).Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol 114: 551-571.
80. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M. (2012).Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol 72: 517-524.
81. Frost B, Diamond MI. (2010). Prion-like mechanisms in neurodegenerative disease. Nat Rev Neurosci 11: 155-159.
82. Frost B, Jacks RL, Diamond MI. (2009). Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845-12852.
83. Fujishiro J, Tsuboi Y, Lin WL, Uchikado H, Dickson DW. (2008). Co-localization of tau and α-synuclein in the olfactory bulb in Alzheimer’s disease with amygdale Lewy bodies. Acta Neuropathol 116: 17-24.
84. Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Diaz-Cabiale Z, Rivera A, Ferraro L, Tanganelli S, Tarakanov AO, Garriga P, Narváez JA, et al. (2012). Extrasynaptic neurotransmission in the modulation of brain function. Focus on striatal neuronal-glial networks. Front Physiol 3: 136.
85. George S, Rey NL, Reichenbach N, Steiner JA, Brundin P. (2013). α-Synuclein: The long distance runner. Brain Pathol 23: 350-357.
86. German DC, Manaye KF, White CL 3rd, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DM. (1992). Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32: 667-676.
87. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. (2002). Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human asynuclein. Neuron 34: 521-533.
88. Gibb WR, Scott T, Lees AJ. (1991). Neuronal inclusions of Parkinson’s disease. Mov Disord 6: 2-11.
89. Goedert M. (2015). Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Ab, tau, and asynuclein. Science 349: 1255555.
90. Goedert M, Spillantini MG, Davies SW. (1998). Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 8: 619-632.
91. Goedert M, Klug A, Crowther RA. (2006). Tau protein, the paired helical filament and Alzheimer’s disease. J Alzheimers Dis 9: 195-207.
92. Goedert M, Clavaguera F, Tolnay M. (2010). The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci 33: 317-325.
93. Goedert M, Spillantini MG, Del Tredici K, Braak H. (2013). 100 years of Lewy pathology. Nat Rev Neurol 9: 13-24.
94. Goedert M, Falcon B, Clavaguera F, Tolnay M. (2014). Prionlike mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep 14: 495.
95. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M,Wisniewski HM, Binder LI. (1986). Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cytoskeletal pathology. Proc Nat Acad Sci 83: 4913-4917.
96. GuestWC, Silverman JM, Pokrishevsky E, O’Neill MA, Grad LI, Cashman NR. (2011). Generalization of the prion hypothesis to other neurodegenerative diseases: An imperfect fit? J Toxicol Environ Health A 74: 1433-1459.
97. Guo JL, Lee VM. (2011). Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286: 15317-15331.
98. Guo JL, Lee VM. (2014). Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20: 130-138.
99. Haass C, Kaether C, Thinakaran G, Sisodia S. (2012). Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2: a006270.
100. Haïk S, Faucheux BA, Hauw JJ. (2004). Brain targeting through the autonomous nervous system: Lessons from prion diseases. Trends Mol Med 10: 109-112.
101. Halliday G,McCann H, Shepherd C. (2012). Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson’s disease? Exp Rev Neurother 12: 673-686.
102. Hansen C, Li JY. (2012). Beyond α-synuclein transfer: Pathology propagation in Parkinson’s disease. Trends Mol Med 18: 248-255.
103. Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, et al. (2011). α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121: 715-725.
104. Hawkes CH, Shephard BC, Daniel SE. (1999). Is Parkinson’s disease a primary olfactory disorder? QJM 92: 473-480.
105. Hawkes CH, Del Tredici K, Braak H. (2007). Parkinson’s disease: A dual hit hypothesis. Neuropathol Appl Neurobiol 33: 599-614.
106. Heimer L, van Hoesen GW. (2006). The limbic lobe and its output channels: Implications for emotional functions and adaptive behavior. Neurosci Biobehav Rev 30: 126-147.
107. Herva ME, Spillantini MG. Parkinson’s disease as a member of prion-like disorders. (2015). Virus Res 2017: 38-46.
108. Holmes BB, Diamond MI. (2012). Cellular mechanisms of protein aggregate propagation. Curr Opin Neurol 25: 721-726.
109. Holmes BB, Diamond MI. (2014). Prion-like properties of tau protein: The importance of extracellular tau as a therapeutic target. J Biol Chem 289: 19855-19861.
110. Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI. (2014). Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci 111: E4376-E4385.
111. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björkland T, Wang ZY, Roybon L, Melki R, Li JY. (2014). Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats.ActaNeuropathol 128: 805-820.
112. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33: 1024-1037.
113. Ikeda K, Ikeda S, Yoshimura T, Kato H, Namba M. (1978). Idiopathic Parkinsonism with Lewy-type inclusions in cerebral cortex. A case report. Acta Neuropathol 41: 165-168.
114. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. (2009). Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118: 53-69.
115. Irizarry MC, Growdon W, Gó mez-Isla T, Newell K, George JM, Clayton DF, Hyman BT. (1998). Nigral and cortical Lewy bodies and dystrophicnigral neurites in Parkinson’s disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 15: 112-116.
116. Irwin DJ, Abrams JY, Schonberger LB, LeschekEW, Mills JL, Trojanowski JQ, Lee VM. (2013). Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 70: 462-468.
117. Ishizawa T, Mattila P, Davies P,Wang D, Dickson DW. (2003). Colocalization of tau and α-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62: 389-397.
118. Jackson SJ, Kerridge C, Cooper J, Cavallini A, Falcon B,Cella CV, Landi A, Szekeres PG, Murray TK, Ahmed Z, et al. (2016). Short fibrils constitute the major species of seedcompetent tau in the brains of mice transgenic for human P301S tau. J Neurosci 36: 762-772.
119. Jang H, Boltz D, Webster RG, Smeyne RJ. 2009a. Viral parkinsonism. Biochim Biophys Acta 1792: 714-721.
120. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, Smeyne RJ. 2009b. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci 18: 14063-14068.
121. Jones BE, Yang TZ. (1985). The efferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat. J Comp Neurol 242: 56-92.
122. Jucker M, Walker LC. (2011). Pathogenic protein seeding in Alzheimer’s disease and other neurodegenerative disorders. Ann Neurol 70: 532-540.
123. Jucker M, Walker LC. (2013). Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501: 45-51.
124. Kalaria RN, Stockmeier CA, Harik SI. (1989). Brain microvessels are innervated by locus ceruleus noradrenergic neurons. Neurosci Lett 97: 203-208.
125. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, Uchihara T. (2011). Pale neurites, premature α-synuclein aggregates with centripetal extension from axon collaterals. Brain Pathol 22: 67-78.
126. Kaufman SK, Diamond MI. (2013). Prion-like propagation of protein aggregation and related therapeutic strategies. Neurotherapeutics 10: 371-382.
127. Klos KJ, Ahlskog JE, Josephs KA,Apaydin H, Parisi JE, Boeve BF, DeLucia MW, Dickson DW. (2006). α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66: 1100-1102.
128. Kordower JH, Dodidya HB, Kordower AM, Terpstra B, Baumier K, Madhaven L, Sortwell C, Steece-Collier K, Collier TJ. (2011). Transfer of host-derived α-synuclein to grafted dopaminergic neurons in the rat. Neurobiol Dis 43: 552-557.
129. Kopeikina KJ, Hyman BT, Spires-Jones TL. (2012). Soluble forms of tau are toxic in Alzheimer’s disease. Transl Neurosci 3: 223-233.
130. Kovacech B, Skrabana R, Novak M. (2010). Transition of tau protein from disordered to misordered in Alzheimer’s disease. Neurodeg Dis 7: 24-27.
131. Kuusisto E, Parkkinen L, Alafuzoff I. (2003). Morphogenesis of Lewy bodies: Dissimilar incorporation of α-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62: 1241-1253.
132. Lamberts JT, Hildebrandt EN, Brundin P. (2015). Spreading of α-synuclein in the face of axonal transport deficits in Parkinson’s disease: A speculative synthesis. Neurobiol Dis 77: 276-283.
133. Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, Vrignaud S, Naveilhan P, Galmiche JP, Bruley des Varannes S, Derkinderen P, et al. (2008). Pathological lesions in colonic biopsies during Parkinson’s disease. Gut 57: 1741-1743.
134. Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Brouard A, N’Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, et al. (2010). Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS ONE 5: e12728.
135. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E. (2010). Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 26: 702-706.
136. Lee HJ, Suk JE, Lee KW, Park SH, Blumbergs PC, Gai WP, Lee SJ. (2011). Transmission of synucleinopathies in the enteric nervous system of A53T α-synuclein transgenic mice. Exp Neurobiol 20: 181-188.
137. Lehman NL. (2009). The ubiquitin proteosome system in neuropathology. Acta Neuropathol 118: 329-347.
138. Liberski PP. (2012). Historical overview of prion diseases: A view from afar. Folia Neuropathol 50: 1-12.
139. Lim KH, Tan JMM. (2007). Role of the ubiquitin proteasome system in Parkinson’s disease. BMC Biochem 8: S13.
140. Lingor P, Koch JC, Tönges L, Bähr M. (2012). Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res 349: 289-311.
141. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. (2012). Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7: e31302.
142. Liubashina O, Jolkkonen E, Pitkänen A. (2000). Projections from the central nucleus of the amygdale to the gastric related areas of the dorsal vagal complex: A Phaseolus vulgaris-leucoagglutinin study in the rat. Neurosci Lett 291: 85-88.
143. Luk KC, Song C, O’Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. (2009). Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci 106: 20051-20056.
144. LukKC,Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VMY. 2012a. Intracerebral inoculation of pathological asynuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J ExpMed 209: 975-986.
145. Luk KC, Kehm VM, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VMY. 2012b. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338: 949-953.
146. Malek N, Swallow D, Grosser KA, Anichtchik O, Spillantini M, Grosset DG. (2014). α-Synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s disease-A systematic review. Acta Neurol Scand 130: 59-72.
147. Marien MR, Colpaert FC, Rosenquist AC. (2004). Noradrenergic mechanisms in neurodegenerative diseases: A theory. Brain Res Rev 45: 38-78.
148. Markesbery WR, Jicha GA, Liu H, Schmitt FA. (2009). Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 68: 816-822.
149. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA, Hasegawa M. (2013). Prion-like spreading of pathological α-synuclein in brain. Brain 136: 1128-1138.
150. Masters CL, Selkoe DJ. (2012). Biochemistry of amyloid b-protein and amyloid deposits in Alzheimer’s disease. Cold Spring Harb Perspect Med 2: a006262.
151. McBride PA, Schulz-Schaeffer WJ, Donaldson M, Bruce M, Diringer H, Kretzschmar HA, Beekes M. (2001). Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol 75: 9320-9327.
152. McCann H, Cartwright H, Halliday GM. (2015). Neuropathology of α-synuclein propagation and Braak hypothesis. Mov Disord 31: 152-160.
153. Melki R. (2015). Role of different α-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J Parkinson’s Dis 5: 217-227.
154. Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. (2015). Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation. J Biol Chem 290: 14893-14903.
155. Miwa H, Kubo T, Susuki A, Kondo T. (2006). Intragastric proteasome inhibition induces α-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. Neurosci Lett 401: 146-149.
156. Morrison JH, Foote SL, O’ConnorD, Bloom FE. (1982). Laminar, tangential and regional organization of the nordrenergic innervation of monkey cortex: Dopamin-bhydroxylase immunohistochemistry. Brain Res Bull 9: 309-319.
157. Mougenot AL, Nicot S, Bencsik A, Morignat E, Vechère J, Lakhdar L, Legastelois S, Baron T. (2012). Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33: 2225-2228.
158. Nieuwenhuys R. (1996). The greater limbic system, the emotional motor system and the brain. Progr Brain Res 107: 551-580.
159. Nieuwenhuys R. (1999). Structure and organisation of fibre systems. In The central nervous system of vertebrates, Vol. 1 (ed. Nieuwenhuys R, Ten Donkelaar JH, Nicholson C), pp 113-157. Springer, Berlin.
160. Nonaka T, Watanabe S, Iwatsubo T, Hasegawa M. (2010). Seeded aggregation and toxicity of α-synuclein and tau: Cellular models of neurodegenerative diseases. J Biol Chem 285: 34885-34898.
161. O’Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. (2012). Norepinephrine: A neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res 37: 2496-2512.
162. Olanow CW, Brundin P. (2013). Parkinson’s disease and a synuclein: Is Parkinson’s disease a prion-like disorder? Mov Disord 28: 31-40.
163. Olanow CW, McNaught K. (2006). Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 21: 1806-1823.
164. Olanow CW, McNaught K. (2011). Parkinson’s disease, proteins, and prions: Milestones. 2011. Mov Disord 26: 1056-1071.
165. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita H, Wakabayashi K, Takahashi H. (2008). Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain 131: 642-650.
166. Ozcelik S, Sprenger F, Skachokova Z, Fraser G, Abramowski D, Clavaguera F, Probst A, Frank S,Müller M, Staufenbiel M, et al. (2016). Co-expression of truncated and full-length tau induces severe neurotoxicity. Mol Pychiatry doi: 10.1038/mp.2015.228.
167. Pan T, Kondo S, LeW, Jankovic J. (2008). The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 131: 1969-1978.
168. Pan-Montojo F, AnichtchikO, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, et al. (2010). Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 5: 8762.
169. Pan-Montojo F, Schwarz M,Winkler C, Arnhold M, O’Sullivan GA, Pal A, Said J,MariscoV,Verbavatz JM, Rodrigo-Angulo M, et al. (2012). Environmental toxins trigger PDlike progression via increased α-synuclein release from enteric neurons in mice. Sci Rep 2: 898.
170. Parent M, Parent A. (2010). Substantia nigra and Parkinson’s disease: A brief history of their long and intimate friendship. Can J Neurol Sci 37: 313-319.
171. Pearce RK, Hawkes CH, Daniel SE. (1995). The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10: 429-434.
172. Pearson RC. (1996). Cortical connections and the pathology of Alzheimer’s disease. Neurodegeneration 5: 429-434.
173. Pearson RC, Powell TP. (1989). The neuroanatomy of Alzheimer’s disease. Rev Neurosci 2: 101-122.
174. Pearson RC, Esiri MM, Hiorns RW,Wilcock GK, Powell TP. (1985). Anatomical correlates of the distribution of the pathological changes in the neocortex of Alzheimer’s disease. Proc Natl Acad Sci 82: 4531-4534.
175. Peelaerts W, Bousset L, Van der Peren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. (2015). αSynuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522: 340-344.
176. Polymenidou M, Cleveland DW. (2012). Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 209: 889-893.
177. Pooler AM, Polydoro M, Wegmann S, Nicholls SB, Spires-Jones TL,Hyman BT. (2013). Propagation of tau pathology in Alzheimer’s disease: Identification of novel therapeutic targets. Alzheimers Res Ther 5: 49-57.
178. Pouclet H, Lebouvier T, Coron E, Bruley des Varannes S, Rouaud T, Roy M, Neunlist M, Derkinderen. (2011). A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease. Neurobiol Dis 45: 305-309.
179. Prusiner SB. (1982). Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144.
180. Prusiner SB. (2012). Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336: 1511-1513.
181. Prusiner SB. (2013). Biology and genetics of prions causing neurodegeneration. Annu Rev Genet 47: 601-623.
182. Prusiner SB,Woerman AL, Mordes DA,Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, et al. (2015). Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci 112: E5308-E5317.
183. Quilty MC, King AE, Gai WP, Pountney DL,West AK, Vickers JC, Dickson TC. (2006). α-Synuclein is upregulated in neurons in response to chronic oxidative stress and is associated with neuroprotection. Exp Neurol 199: 249-256.
184. Rapoport SI. (1988). Brain evolution and Alzheimer’s disease. Rev Neurol (Paris) 144: 79-90.
185. Rapoport SI. (1989).Hypothesis: Alzheimer’s disease is a phylogenetic disease. Med Hypotheses 29: 147-150.
186. Rapoport SI. (1990). Integrated phylogeny of the primate brain, with special reference to humans and their diseases. Brain Res Rev 15: 267-294.
187. Rapoport SI. (1999). How did the human brain evolve? A proposal based on new evidence from in vivo imaging during attention and ideation. Brain Res Bull 50: 149-165.
188. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, et al. (2014). Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology in neurodegeneration in mice and monkeys. Ann Neurol 75: 351-362.
189. Rey NL, Petit GH, Bousset L, Melki R, Brundin P. (2013). Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126: 555-573.
190. Richards WG, Sugarbaker DJ. (1995). Neuronal control esophageal function. Chest Surg Clin North Am 5: 157-171.
191. Rubinsztein DC. (2006). The roles of intracellular proteindegradation pathways in neurodegeneration. Nature 443: 780-786.
192. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee LS, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DL, et al. (2014). Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci 111: 10732-10737.
193. Saha AR, Hill J, Utton MA, Assuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, et al. (2004). Parkinson’s disease α-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 117: 1017-1024.
194. Samuels ER, Szabadi E. (2009). Functional neuroanatomy of the noradrenergic locus coeruleus: Its roles in the regulation of arousal and autonomic function. Part I: Principles of functional organization. Curr Neuropharmacol 6: 235-253.
195. SandersDW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, et al. (2014). Distinct tau prion strains propagate in cells and define different tauopathies. Neuron 82: 1271-1288.
196. Saper CB,Weiner BH, German DC. (1987). Axonal and transneuronal transport in the transmission of neurological disease: Potential role in system degenerations, including Alzheimer’s disease. Neuroscience 23: 389-398.
197. Sara SJ. (2009). The locus coeruleus and noradrenergic modulation of cognition. Nature Rev Neurosci 10: 211-223.
198. Shannon KM, Deshavarzian A,Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. (2012). α-Synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord 27: 709-715.
199. Shipley MT, Halloran FJ, de la Torre J. (1985). Surprisingly rich projection from the locus coeruleus to the olfactory bulb in the rat. Brain Res 329: 294-299.
200. Sims KS, Williams RS. (1990). The human amygdaloid complex: A cytologic and histochemical atlas using Nissl, myelin, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate diaphorese staining. Neuroscience 36: 449-472.
201. Smethurst P, Sidle KC, Hardy J. (2015). Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TPD-43) in amyotrophic lateral sclerosis (ALS). Neuropathol Appl Neurol 41: 578-597.
202. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. (1997). α-Synuclein in Lewy bodies. Nature 388: 839-840.
203. Stokholm MS, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. (2016). Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson’s disease patients. Ann Neurol 79: 940-949.
204. Stokin GB, Goldstein LS. (2006). Axonal transport and Alzheimer’s disease. Ann Rev Biochem 75: 607-627.
205. Supattapone S. (2015). Expanding the prion disease repertoire. Proc Natl Acad Sci 112: 11748-11749.
206. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT. (2015). Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol 78: 522-529.
207. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, et al. (2011). Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 31: 2511-2525.
208. Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL,Hyman BT. (2012). The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181: 1426-1435.
209. Takeda S, Yamazaki K, Miyakawa T, Arai H. (1993). Parkinson’s disease with involvement of the parasympathetic ganglia. Acta Neuropathol 86: 397-398.
210. Tofaris GK, Spillantini MG. (2007). Physiological and pathological properties of α-synuclein. Cell Mol Life Sci 64: 2194-2201.
211. Tsigelny IF, Sharikov Y,WrasidioW, Gonzalez T, Desplats PA, Crews L, Spencer B, Masliah E. (2012). Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J 279: 1000-1013.
212. Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, Courtney JM, Kim JK, Barclay AM, Kendall A, et al. (2016). Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol 23: 409-415.
213. Ulusoy A, Rusconi R, Perez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, Di Monte DA. (2013). Caudo-rostral brain spreading of a synuclein through vagal connections. EMBO Mol Med 5: 1051-1059.
214. Upadhya SC, Hegde AN. 2007a. Role of the ubiquitin proteasome system in Alzheimer’s disease. BMC Biochem 8: S12.
215. Upadhya SC, Hegde AN. 2007b. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci 30: 587-595.
216. Utton MA, Connell J, Asuni AA, van Slegtenhorst M, Hutton M, de Silva R, Lees AJ, Miller CC, Anderton BH. (2002). The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. Neurosci 22: 6394-6400.
217. Van Ba AT, Imberdis T, PerrierV. (2013). Fromprion disease to prion-like propagation mechanisms of neurodegenerative diseases. Int J Cell Biol 2013: 975832.
218. van de Berg WD, Hepp DH, Dijkstra AA, Rozemuller JA, Berendse HW, Foncke E. (2012). Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson’s disease. Parkinsonism Relat Disord 18: S28-S30.
219. Vella LJ, Sharples RA, Lawson VA,Masters CL, Cappai R, Hill AF. (2007). Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol 211: 582-590.
220. Volpicelli-Daley LA, Luk KC, Patel PT, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowki JQ, Lee VM. (2011). Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72: 57-71.
221. Volpicelli-Daley LA, Gamble KL, Schultheiss CE, Riddle DM, West AB, Lee VM. (2014). Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.Mol Biol Cell 25: 4010-4023.
222. von Bergen M, Barghorn S, Biernat J,Mandelkow EM, Mandelkow E. (2005). Tau aggregation is driven by a transition from random coil to b sheet structure. Biochim Biophys Acta 1739: 158-166.
223. Wakabayashi K, Takahashi H. 1997a. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 38 (Suppl 2): 2-7.
224. Wakabayashi K, Takahashi H. 1997b. The intermediolateral nucleus and Clarke’s column in Parkinson’s disease. Acta Neuropathol 94: 287-289.
225. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. (1988). Parkinson’s disease: The presence of Lewy bodies in Auerbach’s andMeissner’s plexuses. ActaNeuropathol 76: 217-221.
226. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. (1989). Lewy bodies in the enteric nervous system in Parkinson’s disease. Arch Histol Cytol 52 (Suppl): 191-194.
227. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. (1990). Parkinson’s disease: An immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79: 581-583.
228. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. 1993. Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. Adv Neurol 60: 609-612.
229. Wakabayashi K, Hansen LA,Masliah E. (1995). Cortical Lewy body-containing neurons are pyramidal cells: Laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol 89: 404-408.
230. Walker LC, Jucker M. (2015). Neurodegenerative diseases: Expanding the prion concept.Ann RevNeurosci 38: 87-103.
231. Walker LC, Diamond MI, Duff KE,Hyman BT. (2012).Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 70: 304-310.
232. Walsh DM, Selkoe DJ. (2016). A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 17: 251-260.
233. Watts JC, Giles K, Oehler A, Middletond L, Dexter DT, Gentleman SM, DeArmond SJ, Prusiner SB. (2013). Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci 110: 19555-19560.
234. Woerman AL, Stöhr J, Aoyagi A, Rampersaud R, Krejciovaa Z, Watts JC, Ohyama T, Patel S, Widjaja K, Oehler A, et al. (2015). Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci 112: E4949-E4958.
235. Wu JW, Herman M, Liu I, et al. (2013). Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288: 1856-1870.